Building on Good Foundations: Constructing a Research Data Management Program for a Research University

Objectives: The director of the university health sciences library (DHSL) and the new director of research data management (DRDM) must develop an eighteen-month plan to create a research data management program for the entire university. The program needs to support mandated data management plans and sharing, and encourage good data management practices throughout the institution. Methods: Collaborating with constituent groups, the DRDM worked with the DHSL to create a roadmap to deploy research data support across the university. Building on early work done at research and health sciences libraries with well-developed research data management services, the team opted not to conduct extensive faculty and research needs assessment regarding data management, assuming that discipline research data needs are similar from institution to institution. A strengths, weaknesses, opportunities, and threats (SWOT) analysis was done to assess the data landscape of the university and identify areas where further professional development would be helpful for the DRDM and DHSL. The university website was used to identify researchers who seemed to be working with data, and these people were contacted with a series of open ended questions. The literature was reviewed to identify best practices and tools for use in research data management. Results: The program started with targeted meetings and presentations to faculty. The team assessed and took steps to address team knowledge deficits. Collaborative relationships were developed with liaison librarians in both libraries to extend their awareness of research data management and provide appropriate referrals. Plans were made to develop and share a core curriculum with liaison librarians for instruction in their areas. A communication plan was developed with the aid of the libraries\u27 communication officer and web developer. Strategic partnerships were identified and pursued. Progress will be assessed to ensure that the needs of the research community are being met

Starting a Research Data Management Program Based in a University Library

As the need for research data management grows, many libraries are considering adding data services to help with the research mission of their institution. The Virginia Commonwealth University (VCU) Libraries created a position and hired a director of research data management in September 2013. The position was new to the libraries and the university. With the backing of the library administration, a plan for building relationships with VCU faculty, researchers, students, service and resource providers, including grant administrators, was developed to educate and engage the community in data management plan writing and research data management training

ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

RAS gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K and RB pathways. Within the MAPK pathway ERK1/2 proteins exert a bottleneck function for transmitting mitogenic signals and activating cytoplasmic and nuclear targets. In view of disappointing anti-tumor activity and toxicity of continuously applied MEK inhibitors in patients with KRAS mutant lung cancer, research has recently focused on ERK1/2 proteins as therapeutic targets and on ERK inhibitors for their ability to prevent bypass and feedback pathway activation. Here we show that intermittent application of the novel and selective ATP-competitive ERK1/2 inhibitor LY3214996 exerts single-agent activity in patient-derived xenograft (PDX) models of RAS mutant lung cancer. Combination treatments were well tolerated and resulted in synergistic (ERKi plus PI3K/mTORi LY3023414) and additive (ERKi plus CDK4/6i abemaciclib) tumor growth inhibition in PDX models. Future clinical trials are required to investigate if intermittent ERK inhibitor-based treatment schedules can overcome toxicities observed with continuous MEK inhibition and - equally important - to identify biomarkers for patient stratification

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Moonlighting Presents Around Town : An Entertaining Promotional Guide With a Focus on Live Music (May 28-June 10, 1997)

Burgandy and WhiteWas a Flyer/Magazine, Double-SidedMoonlightin

Homemakers' Opinions About Selected Meats: A Nationwide Survey

Excerpts from the report Introduction: This study of homemakers' opinions about selected meats was undertaken to provide insights into ways of planning more adequate programs of research, education, and promotion for the mutual benefit of the consumer and the meat industry. The findings presented here are based on personal interviews conducted with 3,099 homemakers during 1967. These homemakers represented a cross-section of private households located in both urban and rural areas throughout the 48 conterminous States. Respondents were selected entirely by area probability sampling procedures